Guillain-Barré syndrome following pandemic (H1N1) 2009 influenza A immunisation in Victoria: a self-controlled case series

The administration of pandemic (H1N1) 2009 influenza A vaccine as part of the pandemic response presented challenges for vaccine safety authorities internationally. The monovalent H1N1 vaccine used in Australia was an egg-culture-based, inactivated, split-virion vaccine, with a demonstrated safety profile similar to that of the seasonal trivalent influenza vaccine (TIV). Postmarketing active surveillance through Phase IV clinical trials is required for potential rare adverse events following immunisation (AEFI), such as Guillain-Barré syndrome (GBS). In 1976–1977, H1N1 immunisation was associated with GBS in the United States. A relative incidence (RI) of 7.6 (95% CI, 6.7–8.6) was reported. This correlated with an estimated excess of nine cases of GBS per million vaccinations in the 42 days after immunisation. Two subsequent studies using the United Kingdom General Practice Research Database (1990–2005) found no association between influenza vaccine and GBS. A Canadian study between influenza vaccination in Ontario and subsequent hospital admission for GBS (RI, 1.45; 95% CI, 1.05–1.99), but reported no increase in GBS at the population level after a mass influenza vaccination in Ontario beginning in 2000. The estimated frequency of influenza illness-related GBS is four to seven times higher than the estimated frequency for influenza vaccine-associated GBS. A literature review (1950–2008) found that, with rare exceptions, associations between vaccines and GBS have been only temporal with little evidence to support a causal association. Challenges for studies examining the epidemiology of GBS include diagnostic uncertainty in identified cases. Additionally, in the absence of influenza vaccine registries, there is often uncertainty in determining the number of vaccines administered. Our study aimed to explore any potential association between monovalent H1N1 vaccine and/or H1N1-containing TIV, and the occurrence of GBS.

Methods

Case ascertainment

An active surveillance system for GBS was established in 10 hospitals in Victoria, Australia. Researchers based at each site identified cases prospectively (admissions and neurophysiology test results) and retrospectively using GBS discharge coding (International Classification of Diseases, 10th revision, Australian modification: G61.0). Research assistants obtained informed consent once “possible” GBS cases were identified. Study information statements and consent forms were mailed to GBS cases identified retrospectively. A detailed immunisation history was obtained from study participants and their primary health care physician (following patient consent).

GBS diagnosis

Two neurologists, a hospital site neurologist and a study investigator (L.K. or V.R.-C.), confirmed the diagnosis of GBS according to the Brighton Collaboration definition (Box 1). Reviewers were blinded to vaccine history. Cases identified retrospectively were interviewed and additional information was collected from the patient’s medical record and the patient’s general practitioner. The Australian Childhood Immunisation Register was accessed to obtain immunisation information for children under 7 years of age.

The study was conducted from 30 September 2009 to 30 September 2010. Monovalent H1N1 vaccine (Panvac, CSL Limited) was available to adults from 30 September 2009 and
to children aged < 10 years in December 2009. The monovalent H1N1 vaccine was available until the program ended 31 December 2010. The TIV (Fluvax, CSL Limited; Vaxigrip, Sanofi Pasteur; Influvac, Abbott) was available from 1 March 2010 to 30 September 2010 and contained A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008.

Self-controlled case series

The self-controlled case series (SCCS) method is an established method to assess vaccine safety9-12 (see the accompanying commentary by Hawken and Wilson [page 578]). It tests the null hypothesis that the incidence rate of events (incident GBS cases) is the same during a set period (risk period) after an exposure of interest (H1N1-containing vaccination) compared with the rate outside of this risk period. The method has the advantage of only requiring cases and of implicit control for confounding by non-time-varying variables.

As in previous studies, it was assumed that if vaccination was associated with an excess risk, GBS would present within 42 days.4,13 The background rate was adjusted for temporary delays in vaccination following GBS diagnosis by removing a 28-day prevaccination period. The analysis included the time-varying variables of trivalent and monovalent H1N1 vaccine, as well as month administered, and assumed that incidence followed a Poisson distribution conditional on the number of events that an individual experienced. We used standard and pseudolikelihood methods. The pseudolikelihood method was used to allow for the vaccine being contraindicated following the GBS diagnosis.14 The primary analysis included first episodes of confirmed cases (Brighton level 1–4), excluding those with incomplete immunisation history. Sensitivity analyses included: dropping the monthly adjustment; using 2-week risk periods (0–13, 14–27 and 28–42 days); including second episodes; restricting to cases of higher certainty (Brighton level 1–2); including cases not confirmed as GBS; and including cases without a complete immunisation history.

A sample size calculation was undertaken before the study.15 Assuming a 0–42-day risk “window” during an observation period of 1 year where 20% of the population were vaccinated, 60 participants were required to demonstrate an RI of 8 (as documented in 1976) with 90% power, allowing for 30% misclassification.

We reviewed the Victorian GBS admissions (2004–2009) and identified the 10 participating hospitals that admitted about 60% of the state’s GBS cases (personal communication, H C). Statistical calculations were performed using Stata, version 10 (StataCorp). The human research ethics committee at each participating hospital approved the study.

Results

Sixty-six cases of probable GBS were identified in the 12-month study period (Box 2). Three cases were excluded, leaving 63 GBS episodes in 62 individuals. Of these, nine were excluded, as on review they did not meet diagnostic criteria for GBS. Four further confirmed cases were excluded, as the date of onset of symptoms predated the availability of the monovalent H1N1 vaccine. In six cases, data were only available from the hospital medical record (ie, neither the patient nor primary care physician were available). These cases with incomplete immunisation histories were excluded from the primary analysis, leaving 44 cases.

The GBS cases were in people aged 7–95 years (median, 48 years). The male to female ratio was 1.1:1. There were 54 confirmed GBS cases in the 12-month period at the 10 Victorian hospital sites. Based on the fact that

---

### Table 1: Brighton Collaboration case definition for Guillain-Barré syndrome (GBS)*

<table>
<thead>
<tr>
<th>Diagnostic certainty</th>
<th>Clinical criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Level 1</strong></td>
<td>Bilateral and flaccid weakness of the limbs and</td>
</tr>
<tr>
<td></td>
<td>Decreased or absent deep tendon reflexes in weak limbs and</td>
</tr>
<tr>
<td></td>
<td>Monophasic illness pattern, with interval between onset and nadir of weakness between 12 hours and 28 days, and subsequent clinical plateau and</td>
</tr>
<tr>
<td></td>
<td>Electrophysiologic findings consistent with GBS and</td>
</tr>
<tr>
<td></td>
<td>Cytoalbuminologic dissociation (ie, elevation of CSF protein level above laboratory normal value, and CSF total white cell count &lt; 50 cells/μL) and</td>
</tr>
<tr>
<td></td>
<td>Absence of an identified alternative diagnosis for weakness</td>
</tr>
<tr>
<td><strong>Level 2</strong></td>
<td>Bilateral and flaccid weakness of the limbs and</td>
</tr>
<tr>
<td></td>
<td>Decreased or absent deep tendon reflexes in weak limbs and</td>
</tr>
<tr>
<td></td>
<td>Monophasic illness pattern, with interval between onset and nadir of weakness between 12 hours and 28 days, and subsequent clinical plateau and</td>
</tr>
<tr>
<td></td>
<td>CSF total white cell count &lt; 50 cells/μL (with or without CSF protein elevation above laboratory reference range) or, if CSF not collected or results not available, electrophysiologic studies consistent with GBS and</td>
</tr>
<tr>
<td></td>
<td>Absence of identified alternative diagnosis for weakness</td>
</tr>
<tr>
<td><strong>Level 3</strong></td>
<td>Bilateral and flaccid weakness of the limbs and</td>
</tr>
<tr>
<td></td>
<td>Decreased or absent deep tendon reflexes in weak limbs and</td>
</tr>
<tr>
<td></td>
<td>Monophasic illness pattern, with interval between onset and nadir of weakness between 12 hours and 28 days, and subsequent clinical plateau and</td>
</tr>
<tr>
<td></td>
<td>Absence of identified alternative diagnosis for weakness</td>
</tr>
<tr>
<td><strong>Level 4a</strong></td>
<td>GBS based on a clear statement from a treating neurologist that GBS is the diagnosis being present in the medical record and there being no contradictory information</td>
</tr>
</tbody>
</table>

CSF = cerebrospinal fluid. *Adapted from Sejvar et al.2
2 Guillain-Barré syndrome active study — flow diagram

67 cases per year expected*
66 probable cases identified
54 confirmed cases
50 cases analysed:
  - 37 Brighton level 1–2
  - 13 Brighton level 3–4a

12 excluded:
  - 2 opted out
  - 1 interhospital transfer
  - 9 not GBS

4 excluded (symptoms onset before 30 Sep 2009)

* Based on background rates from the Victorian Admitted Episodes Dataset and the Victorian Emergency Minimum Dataset. † Diagnosed between 30 Sep 2009 and 30 Sep 2010.

these sites accounted for about 60% of GBS cases and the Victorian estimated resident population at 31 December 2009 was 5,496,000, the annual incidence of GBS was calculated to be 1.7 per 100,000 population. Overall, 37 patients met Brighton level 1–2 and 13 patients met level 3–4a (Box 2). The second episode in the individual with two presentations was level 4a. Monovalent H1N1 vaccine had been received by 11 patients (eight Brighton level 1–2, two level 3–4a and one without GBS). A total of 12 patients had received TIV within the study period, or within 6 weeks of commencement of the study period (of these, seven were Brighton level 1–2, four were level 3–4a and one did not have GBS). Two individuals received both vaccines in the study period.

SCCS results

Three cases of GBS occurred within 42 days of receipt of monovalent H1N1 vaccine; one within each 2-week period following receipt of vaccine (at Days 9, 24 and 40; Box 3). Of these, two were Brighton level 1 and one was level 2. One case of GBS occurred within 42 days of seasonal TIV (at Day 27; Brighton level 4).

Following GBS diagnosis, two cases received seasonal TIV, but none received the monovalent H1N1 vaccine. The RI estimate from the primary analysis using the standard method was 3.41 (95% CI, 0.78–14.97), compared with the pseudo-likelihood estimate of 3.17 (bootstrap 95% CI, 0–16.78). As the change was <25%, the standard method was chosen as the primary analysis. SCCS sensitivity analyses produced an estimated non-significant RI rate of between 2 and 3 (Box 3). Following TIV, there was one case in the risk period and the RI was estimated as 0.69 (95% CI, 0.08–5.64). For TIV or monovalent H1N1 vaccine, there were four cases in the risk period and the RI was estimated at 1.71 (95% CI, 0.54–5.39).

Discussion

Active surveillance in Australia for GBS following pandemic (H1N1) 2009 influenza A immunisation was crucial, given the increased risk found in the US in 1976. Our active GBS surveillance in Victoria was powered to detect a signal similar to the eightfold increase identified in that study. Our main analysis showed no evidence of a significantly increased risk of GBS following H1N1 immunisation. Three cases of GBS were identified within 42 days following administration of monovalent H1N1 vaccine, with an RI estimate of 3.41 (95% CI, 0.78–14.97).

Active GBS surveillance after pandemic H1N1/09 influenza immunisation was also undertaken in the US, using a number of different methodologies. The Vaccine Safety Datalink Project (2009–2010) used the self-controlled risk interval analysis, with the risk difference following monovalent influenza vaccine being five cases per million doses (95% CI, 0.5–9.5). Wise and colleagues, using active, population-based surveillance for incident GBS cases among 45 million people, observed a small increase, with 0.74 excess cases per million monovalent H1N1 vaccine doses (95% CI, 0.42–1.56). Yih and colleagues, using the Post-Licensure Rapid Immunization Safety Monitoring cohort active surveillance system, found an elevated but not statistically significant incidence rate ratio following receipt of monovalent H1N1 vaccine (2.5; 95% CI, 0.42–15.0). No statistically significant increase was identified in a European case–control series of monovalent H1N1 vaccine and GBS. Case recruitment varied considerably by region — there were 104 confirmed cases from five European countries with an adjusted odds ratio risk of GBS of 1.0 (95% CI, 0.3–2.7). A United Kingdom study assessed GBS risk following an AS03 adjuvanted H1N1 vaccine using an SCCS analysis of cases identified from electronic hospital episode data. It found that the RI was

3 Pandemic (H1N1) 2009 influenza A immunisation and Guillain-Barré syndrome: relative incidence (RI) estimates from the self-controlled case series with a 42-day postvaccination risk window

<table>
<thead>
<tr>
<th>Model</th>
<th>RI (95% CI)</th>
<th>Cases in risk window (0–42 days)</th>
<th>Cases in analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Base*</td>
<td>3.41 (0.78–14.97)</td>
<td>3</td>
<td>44</td>
</tr>
<tr>
<td>No seasonal trivalent influenza vaccine</td>
<td>3.39 (0.77–14.91)</td>
<td>3</td>
<td>44</td>
</tr>
<tr>
<td>No period adjustment</td>
<td>2.92 (0.75–11.31)</td>
<td>3</td>
<td>44</td>
</tr>
<tr>
<td>Three 2-week periods</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–13 days</td>
<td>3.74 (0.41–34.05)</td>
<td>1</td>
<td>44</td>
</tr>
<tr>
<td>14–27 days</td>
<td>3.35 (0.38–29.64)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>28–41 days</td>
<td>3.19 (0.35–28.67)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Only Brighton level 1–2 cases</td>
<td>3.99 (0.82–19.55)</td>
<td>3</td>
<td>35</td>
</tr>
<tr>
<td>Include unconfirmed cases</td>
<td>2.71 (0.62–11.85)</td>
<td>3</td>
<td>49</td>
</tr>
<tr>
<td>Include incomplete vaccine history</td>
<td>3.25 (0.75–14.21)</td>
<td>3</td>
<td>50</td>
</tr>
<tr>
<td>Include incomplete vaccine history and second episode†</td>
<td>3.34 (0.76–14.59)</td>
<td>3</td>
<td>51</td>
</tr>
<tr>
<td>Include all</td>
<td>2.25 (0.54–9.37)</td>
<td>3</td>
<td>57</td>
</tr>
</tbody>
</table>

* Standard method with a monthly period effect, Brighton level 1–4, first episode, complete vaccine history, 28-day prevaccination exclusion, seasonal trivalent influenza vaccine included. † The case with two events did not have vaccine history recorded; to investigate adding in the second episode, we also included incomplete episodes.
not significant (1.05; 95% CI, 0.37–2.24), with limited Brighton GBS case validation because of a low reporting rate from neurologists.23

Passive AEfi surveillance for conditions such as GBS has the potential limitation of poor case ascertainment. In China, a study detected 11 cases of GBS out of 89 million distributed doses of H1N1 vaccine.22 This compares with the National Vaccine Injury Compensation Program in Korea, which had 22 confirmed cases of GBS (Brighton level 1–3).23

A strength of our study was that it reviewed immunisation records from multiple sources, including hospital and general practitioner records, and included a detailed immunisation interview. By comprehensively reviewing admissions, neurophysiology test results and hospital International Classification of Diseases coding, we believe it is unlikely that any cases were missed at participating hospitals. Detailed review identified nine out of 63 cases (14.3%) that were not GBS according to the Brighton criteria. This is less than the 31% misclassification rate described elsewhere.13

A potential study limitation was the low rate of uptake for H1N1 vaccine, as higher population coverage rates increases the power to detect a difference in GBS incidence. Australia did not have an influenza immunisation register, but a representative survey of over 10 000 adults estimated that 18.9% of Australians had received monovalent H1N1 influenza vaccine by December 2009, which was close to our study power calculation of 20% coverage.24 A higher coverage rate (42.6%) was found in individuals aged 65 years and over who are routinely funded to receive the seasonal TV. A second limitation of the study was the lack of complete immunisation history for six cases, with data only available from hospital records. Including these cases in the SCCS analysis did not significantly alter the relative incidence from hospital records. Including these cases in the SCCS analysis did not significantly alter the relative incidence from

Our study was not powered to detect a small increase in GBS following H1N1 vaccination but was linked to the World Health Organization’s Global Vaccine Safety Initiative, which was powered to detect lower increases in the RI of GBS following H1N1 vaccination and to provide data on regional differences. A preliminary unpublished analysis of these data was recently presented and found an RI of GBS in the 42 days following H1N1 vaccination of 2.86 (95% CI, 1.87–4.34).26 This suggests that there was an increase in GBS cases following immunisation (of a similar magnitude estimated in our study), but that this increase is smaller than that described with the 1976 vaccine. This small increase in GBS risk must be considered in the context of the benefits of influenza vaccinations, including potential protection against severe influenza and GBS due to influenza infection.

In this Victorian study, we found that only a small proportion of GBS cases occurred following pandemic influenza immunisation, and that the RI of GBS following immunisation was not statistically different to the baseline rate. The study could not exclude smaller increases in the RI, which have been suggested in studies among larger populations with higher vaccine coverage23 and the preliminary analysis of an international meta-analysis of GBS monitoring studies.26 This highlights the role of international collaborations in active AEfi surveillance, to carefully assess the risks and benefits of population immunisation programs.

Acknowledgements: We thank Anselin Swanson, Sherisse Celestino, Natalie Teasdale, Miranda Pellissier and Anne Lickliter for their help in data collection as the research assistants at the GBS active study sites.

Competing interests: This study was funded by CSL Ltd as part of postmarketing surveillance, with financial support for study nurses at each site. The funder did not have any role in data collection, analysis or the decision to publish.

Received 26 Mar 2012, accepted 19 Aug 2012.


The self-controlled case series method for evaluating safety of vaccines

Using cases as their own controls potentially provides stronger evidence for analysing adverse events following vaccination

Maintaining public confidence in vaccines requires having effective postmarketing vaccine safety surveillance systems in place to rapidly address emerging concerns about vaccine safety. However, conducting studies of vaccine safety presents several challenges for traditional observational study designs. Important differences may exist between vaccinated and unvaccinated individuals that could confound the true association between vaccination and adverse events. In practice, it is often difficult or impossible to adequately control statistically for these differences, either because confounders are unmeasured or unmeasurable, or because of the scarcity of unvaccinated controls when studying population-wide immunisation programs.

In this issue of the Journal, Crawford and colleagues used the self-controlled case series (SCCS) method to assess the association between pandemic (H1N1) 2009 influenza vaccination and the occurrence of Guillain-Barré syndrome. The SCCS design, which was developed by C.Paddy Farrington, has emerged as a gold-standard method for studying adverse events following vaccination. In contrast to other designs such as cohort and case-control, the SCCS is a case-only design, requiring information only on individuals who have received the exposure (vaccination) and experienced one or more adverse events of interest, thus avoiding problems related to differences between vaccinated and unvaccinated individuals.

In the SCCS design, the observation time for each person is subdivided into exposed (risk) segments where it is biologically plausible that the exposure (vaccination) could cause the event, and unexposed (control) segments where it is biologically implausible that the exposure could cause the event. Each person is, in essence, compared with him- or herself in exposed versus unexposed time periods.

Important differences may exist between vaccinated and unvaccinated individuals that could confound the true association of interest between vaccination and adverse events. In practice, it is often difficult or impossible to adequately control statistically for these differences, either because confounders are unmeasured or unmeasurable, or because of the scarcity of unvaccinated controls when studying population-wide immunisation programs.

In this issue of the Journal, Crawford and colleagues used the self-controlled case series (SCCS) method to assess the association between pandemic (H1N1) 2009 influenza vaccination and the occurrence of Guillain-Barré syndrome. The SCCS design, which was developed by C.Paddy Farrington, has emerged as a gold-standard method for studying adverse events following vaccination. In contrast to other designs such as cohort and case-control, the SCCS is a case-only design, requiring information only on individuals who have received the exposure (vaccination) and experienced one or more adverse events of interest, thus avoiding problems related to differences between vaccinated and unvaccinated individuals.

In the SCCS design, the observation time for each person is subdivided into exposed (risk) segments where it is biologically plausible that the exposure (vaccination) could cause the event, and unexposed (control) segments where it is biologically implausible that the exposure could cause the event. Each person is, in essence, compared with him- or herself in exposed versus unexposed time periods. This cancels out fixed individual factors (e.g., sex, socioeconomic status) and thus completely adjusts for the effect of these potential confounders. The incidence of events in risk and control periods is calculated by determining the number of events per person/time at risk (i.e., events/day). An overall relative incidence (RI) is then calculated by obtaining the ratio of incidence levels in the risk period compared with the control period. In order to calculate valid confidence intervals for RI estimates, statistical modelling is required. The SCCS model can be fitted using a
The SCCS design has some important limitations. First, like other observational designs, it is susceptible to confounding from coincident temporal exposures (unmeasured exposures that occur during the same observation period as the exposure of interest; for example, a second vaccine given at the same time as the vaccine of interest). Second, also like other observational vaccine safety designs, the SCCS is susceptible to the healthy vaccinee effect, whereby vaccination is deferred for patients in ill health in the week preceding a scheduled vaccination. This would be necessary, for example, if individuals were to receive a second MMR vaccination at 18 months.

The SCCS design has some important limitations. First, like other observational designs, it is susceptible to confounding from coincident temporal exposures (unmeasured exposures that occur during the same observation period as the exposure of interest; for example, a second vaccine given at the same time as the vaccine of interest). Second, also like other observational vaccine safety designs, the SCCS is susceptible to the healthy vaccinee effect, whereby vaccination is deferred for patients in ill health in the week preceding a scheduled vaccination. This results in vaccinated individuals appearing healthy immediately before and after vaccination, potentially washing out effects within the first few days following vaccination. Third, the method is not well suited to situations where the occurrence of events truncates or curtails the duration of the exposure period (eg, death). However, extensions to the model have been developed that address these issues.5,9-11

The SCCS is an important method for studying adverse events following vaccination. It is well suited to use in linked health administrative data and is quick to implement, allowing safety surveillance studies to be undertaken in a short time frame. In many cases, SCCS studies can provide stronger evidence than even a large cohort study, since they provide complete control of individual-level confounders and often have as much, or more, power.9 For more detailed information, we recommend the following website: http://statistics.open.ac.uk/sccs.

Competing Interests: No relevant disclosures.

Provenance: Commissioned; not externally peer reviewed.